Scott Robertson

Scott Robertson is a seasoned executive with extensive experience in business development and finance within the biopharma and agricultural sectors. Currently serving as the Chief Business Officer and Chief Financial Officer at Star Therapeutics since January 2024 and as a Board Member and Audit Committee Chair at Bicara Therapeutics since October 2023, Scott has also held significant roles at DICE Therapeutics, including Chief Business & Financial Officer during its acquisition by Eli Lilly & Company. Prior to that, Scott was a lecturer at the University of California, Berkeley, Haas School of Business since July 2015, and served on the board of Hexima Limited, where responsibilities included chairing the Compensation Committee and participating in the Audit Committee. Previous experience encompasses leading M&A and business development efforts at DuPont, as well as venture capital roles at MPM Capital and Merrill Lynch. Scott holds an MBA from the University of Southern California and has a degree from the University of California, Berkeley, Haas School of Business.